Ranquilon versus Afobazol for anxiety in neurasthenia and adjustment disorders: open randomized phase IV comparison
T. A. Karavayeva, A. N. Barinov, I. V. Egorov, E. Yu. Ebzeeva, K. A. Ishchenko · 2026 · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 126(7):51–62
Published 2026-08-07.
Reported findings and study design
The open trial reported ≥50% HARS improvement in 63.3% (62 patients) with Ranquilon versus 49.0% (49 patients) with Afobazol at day 29 (p<0.043).
Dose, route and schedule
Ranquilon 6 mg/day or Afobazol (fabomotizole) 30 mg/day orally for 28 days. Study methods, not a recommended personal regimen.
Protocol source ↗ · Publisher abstract and references checked; full 2026 article not accessed.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Reported ≥50% HARS response | 63.3% (62 patients) versus 49.0% (49 patients) | Day 29 · p<0.043 |
| Arm-level patients with adverse events | 16/100 versus 12/100 | Overall count in abstract is inconsistent; arm-level figures retained as printed · p=0.4150 |
Active-comparator, open-label trial; this is not a blinded placebo comparison. The abstract does not reconcile 62 responders/63.3% with 100 randomized in that arm. Its combined adverse-event patient count is also internally inconsistent; do not silently reconstruct denominators.
Source for the extracted data ↗ · Checked 2026-11-01
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- Active-comparator, open-label trial; this is not a blinded placebo comparison.
- The abstract does not reconcile 62 responders/63.3% with 100 randomized in that arm. Its combined adverse-event patient count is also internally inconsistent; do not silently reconstruct denominators.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Review depth: Publisher abstract and references checked; full 2026 article not accessed.
Related-report group: gb115-phase4-NCT06843044. Reports in this group are not assumed to be independent trials.
Source access and review scope
Publisher abstract and references checked; full 2026 article not accessed.
Recorded source-check date: 2026-11-01. This date does not imply a completed systematic review.
Source type: Original journal publication
Citation and original source
Original source: T. A. Karavayeva, A. N. Barinov, I. V. Egorov, E. Yu. Ebzeeva, K. A. Ishchenko. Ranquilon versus Afobazol for anxiety in neurasthenia and adjustment disorders: open randomized phase IV comparison Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 126(7):51–62 2026.
Molekul research summary: https://molekul.io/research/gb115-phase4-2026. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry